专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090041784A1 Compositions and methods relating to glucagon receptor antibodies 有权
标题翻译：与胰高血糖素受体抗体相关的组合物和方法
公开(公告)号：US20090041784A1
公开(公告)日：2009-02-12
申请号：US11903481
申请日：2007-09-20
申请人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
发明人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
IPC分类号： A61K39/395 , C07K16/18 , C12N15/11 , C12N15/79 , C12N5/06 , C12P21/04 , A61P1/00
CPC分类号： C07K16/2869 , A61K2039/505 , C07K14/723 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
摘要翻译：本公开提供了与抗原结合蛋白特别是特异性结合人胰高血糖素受体的抗体相关的组合物和方法。本公开提供了编码这种抗原结合蛋白的核酸和抗体，以及制备和使用这些抗体的方法，包括通过向需要这种治疗的受试者施用此类抗体来治疗和预防2型糖尿病和相关疾病的方法。

2. 发明授权

US07947809B2 Compositions and methods relating to glucagon receptor antibodies 有权
标题翻译：与胰高血糖素受体抗体相关的组合物和方法
公开(公告)号：US07947809B2
公开(公告)日：2011-05-24
申请号：US11903481
申请日：2007-09-20
申请人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
发明人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
IPC分类号： C12P21/08
CPC分类号： C07K16/2869 , A61K2039/505 , C07K14/723 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
摘要翻译：本公开提供了与抗原结合蛋白特别是特异性结合人胰高血糖素受体的抗体相关的组合物和方法。本公开提供了编码这种抗原结合蛋白的核酸和抗体，以及制备和使用这些抗体的方法，包括通过向需要这种治疗的受试者施用此类抗体来治疗和预防2型糖尿病和相关疾病的方法。

3. 发明授权

US08158759B2 Compositions and methods relating to glucagon receptor antibodies 有权
标题翻译：与胰高血糖素受体抗体相关的组合物和方法
公开(公告)号：US08158759B2
公开(公告)日：2012-04-17
申请号：US13113996
申请日：2011-05-23
申请人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
发明人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
IPC分类号： C12P21/06
CPC分类号： C07K16/2869 , A61K2039/505 , C07K14/723 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
摘要翻译：本公开提供了与抗原结合蛋白特别是特异性结合人胰高血糖素受体的抗体相关的组合物和方法。本公开提供了编码这种抗原结合蛋白的核酸和抗体，以及制备和使用这些抗体的方法，包括通过向需要这种治疗的受试者施用此类抗体来治疗和预防2型糖尿病和相关疾病的方法。

4. 发明申请

US20110223160A1 COMPOSITIONS AND METHODS RELATING TO GLUCAGON RECEPTOR ANTIBODIES 有权
标题翻译：与GLUCAGON受体抗体相关的组合物和方法
公开(公告)号：US20110223160A1
公开(公告)日：2011-09-15
申请号：US13113996
申请日：2011-05-23
申请人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
发明人： Hai Yan , Shaw-Fen Sylvia Hu , Thomas C. Boone , Richard A. Lindberg
IPC分类号： A61K39/395 , C12P21/06 , C12N5/16 , C12N15/63 , C07K16/28 , C07H21/04 , A61P3/10 , A61P3/08
CPC分类号： C07K16/2869 , A61K2039/505 , C07K14/723 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
摘要翻译：本公开提供了与抗原结合蛋白特别是特异性结合人胰高血糖素受体的抗体相关的组合物和方法。本公开提供了编码这种抗原结合蛋白的核酸和抗体，以及制备和使用这些抗体的方法，包括通过向需要这种治疗的受试者施用此类抗体来治疗和预防2型糖尿病和相关疾病的方法。

5. 发明申请

US20120121591A1 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 审中-公开
标题翻译： Kv1.3的选择和磷酸肽抑制剂
公开(公告)号：US20120121591A1
公开(公告)日：2012-05-17
申请号：US13258454
申请日：2010-03-19
申请人： John K. Sullivan , Leslie P. Miranda , Colin V. Gegg , Shaw-Fen Sylvia Hu , Edward J. Belouski , Justin K. Murray , Hung Nguyen , Kenneth W. Walker , Taruna Arora , Frederick W. Jacobsen , Yue-Sheng Li , Thomas C. Boone
发明人： John K. Sullivan , Leslie P. Miranda , Colin V. Gegg , Shaw-Fen Sylvia Hu , Edward J. Belouski , Justin K. Murray , Hung Nguyen , Kenneth W. Walker , Taruna Arora , Frederick W. Jacobsen , Yue-Sheng Li , Thomas C. Boone
IPC分类号： A61K39/395 , C07K14/765 , C07K16/00 , C07K14/47 , C07K19/00 , A61K38/16 , A61P25/00 , A61P3/10 , A61P17/06 , A61P29/00 , A61P11/06 , A61P13/12 , A61P19/08 , A61K38/38 , A61K38/17 , A61P37/06 , A61P17/00 , A61P19/02 , A61P37/08 , A61P9/00 , A61P43/00 , C07K14/00
CPC分类号： C07K16/44 , A61K39/39591 , A61K47/6817 , A61K47/6843 , C07K14/43504 , C07K14/575 , C07K14/605 , C07K14/66 , C07K16/00 , C07K16/18 , C07K16/248 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/55
摘要： Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.
摘要翻译：公开了具有SEQ ID NO：4的氨基酸序列或其药学上可接受的盐的物质组合物，包括包含与ShK，HmK和AETX-K相关的毒素肽类似物的实施方案，以及含有它们的药物组合物或药物以及药学上可接受的载体。一些实施方案包括半衰期延长部分。还公开了预防或减轻多发性硬化症状的复发的方法以及使用该组合物治疗自身免疫病症的方法。

6. 发明申请

US20100172895A1 Human CGRP Receptor Binding Proteins 有权
标题翻译：人CGRP受体结合蛋白
公开(公告)号：US20100172895A1
公开(公告)日：2010-07-08
申请号：US12642711
申请日：2009-12-18
申请人： Thomas C. Boone , David W. Brankow , Colin V. Gegg, JR. , Shaw-Fen Sylvia Hu , Chadwick T. King , Hsieng Sen Lu , Licheng Shi , Cen Xu
发明人： Thomas C. Boone , David W. Brankow , Colin V. Gegg, JR. , Shaw-Fen Sylvia Hu , Chadwick T. King , Hsieng Sen Lu , Licheng Shi , Cen Xu
IPC分类号： A61K39/395 , C12P21/00 , C12N5/10 , C12N5/00 , C07K2/00 , C07K16/00 , C07H21/04
CPC分类号： C07K16/2869 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K2317/21 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
摘要翻译：提供了结合人CGRP受体（CGRP R）的抗原结合蛋白。还提供编码抗原结合蛋白，载体和编码抗原结合蛋白的核酸的核酸。抗原结合蛋白可以抑制CGRP R与CGRP的结合，并且可用于多种CGRP R相关疾病，包括治疗和/或预防偏头痛。

7. 发明申请

US20130071410A1 Human CGRP Receptor Binding Proteins 审中-公开
标题翻译：人CGRP受体结合蛋白
公开(公告)号：US20130071410A1
公开(公告)日：2013-03-21
申请号：US13612615
申请日：2012-09-12
申请人： Thomas C. Boone , David W. Brankow , Colin V. Gegg, JR. , Shaw-Fen Sylvia Hu , Chadwick T. King , Hsieng Sen Lu , Licheng Shi , Cen Xu
发明人： Thomas C. Boone , David W. Brankow , Colin V. Gegg, JR. , Shaw-Fen Sylvia Hu , Chadwick T. King , Hsieng Sen Lu , Licheng Shi , Cen Xu
IPC分类号： A61K39/395 , C12N15/13 , C07H21/04 , A61P25/00 , C12P21/02 , C12N15/63 , C12N1/21 , C12N1/19 , C12N5/10 , C07K16/28 , A61P25/06
CPC分类号： C07K16/2869 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K2317/21 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related, disorders including the treatment and/or prevention of migraine headaches.
摘要翻译：提供了结合人CGRP受体（CGRP R）的抗原结合蛋白。还提供编码抗原结合蛋白，载体和编码抗原结合蛋白的核酸的核酸。抗原结合蛋白可以抑制CGRP R与CGRP的结合，并且可用于多种CGRP R相关疾病，包括治疗和/或预防偏头痛。

8. 发明授权

US09102731B2 Human CGRP receptor binding proteins 有权
标题翻译：人CGRP受体结合蛋白
公开(公告)号：US09102731B2
公开(公告)日：2015-08-11
申请号：US12642711
申请日：2009-12-18
申请人： Thomas C. Boone , David W. Brankow , Colin V. Gegg, Jr. , Shaw-Fen Sylvia Hu , Chadwick T. King , Hsieng Sen Lu , Licheng Shi , Cen Xu
发明人： Thomas C. Boone , David W. Brankow , Colin V. Gegg, Jr. , Shaw-Fen Sylvia Hu , Chadwick T. King , Hsieng Sen Lu , Licheng Shi , Cen Xu
IPC分类号： C07K16/00 , C12P21/08 , C07K16/28
CPC分类号： C07K16/2869 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K2317/21 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/30
摘要： Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
摘要翻译：提供了结合人CGRP受体（CGRP R）的抗原结合蛋白。还提供编码抗原结合蛋白，载体和编码抗原结合蛋白的核酸的核酸。抗原结合蛋白可以抑制CGRP R与CGRP的结合，并且可用于多种CGRP R相关疾病，包括治疗和/或预防偏头痛。

9. 发明授权

US09284378B2 Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof 有权
标题翻译：结合蛋白的人抗原结合蛋白-Klotho，FGF受体及其复合物
公开(公告)号：US09284378B2
公开(公告)日：2016-03-15
申请号：US12960407
申请日：2010-12-03
申请人： Shaw-Fen Sylvia Hu , Ian Foltz , Chadwick Terence King , Yang Li , Taruna Arora
发明人： Shaw-Fen Sylvia Hu , Ian Foltz , Chadwick Terence King , Yang Li , Taruna Arora
IPC分类号： C07K16/28 , C07K16/40 , C07K14/71 , C07K16/18 , A61K39/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K14/71 , C07K16/18 , C07K16/28 , C07K16/40 , C07K2317/21 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/75 , C07K2317/92 , C07K2319/30
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
摘要翻译：本发明提供与抗原结合蛋白有关或衍生自抗原结合蛋白的组合物和方法激活FGF21介导的信号传导。在实施方案中，抗原结合蛋白特异性结合（i）＆amp; bgr; -Klotho; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含α-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合（i）和/或Klotho的多肽; （ii）FGFR1c，FGFR2c，FGFR3c或FGFR4; 或（iii）包含α-Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4之一的复合物。其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这些抗原结合蛋白的方法，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

10. 发明授权

US07833979B2 Toxin peptide therapeutic agents 有权
标题翻译：毒素肽治疗剂
公开(公告)号：US07833979B2
公开(公告)日：2010-11-16
申请号：US11406454
申请日：2006-04-17
申请人： John K. Sullivan , Joseph G. McGivern , Leslie P. Miranda , Hung Q. Nguyen , Kenneth W. Walker , Shaw-Fen Sylvia Hu , Colin V. Gegg , Stefan I. McDonough
发明人： John K. Sullivan , Joseph G. McGivern , Leslie P. Miranda , Hung Q. Nguyen , Kenneth W. Walker , Shaw-Fen Sylvia Hu , Colin V. Gegg , Stefan I. McDonough
IPC分类号： A61K38/00 , C07K14/00
CPC分类号： A61K47/48215 , A61K38/00 , A61K47/60 , C07K14/43504 , C07K2319/30 , C07K2319/55
摘要： Disclosed is a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c (I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
摘要翻译：公开了式（X1）a-（F1）d-（X2）b-（F2）e-（X3）c（Ⅰ）及其多元素的物质组成，其中F1和F2是半衰期延长部分，d和e各自独立地为0或1，条件是d和e中的至少一个为1; X1，X2和X3各自独立地为 - （L）f-P-（L）g-，f和g各自独立地为0或1; P是长度不超过约80个氨基酸残基的毒素肽，其包含至少两个肽内二硫键; L是可选的接头; 并且a，b和c各自独立地为0或1，条件是a，b和c中的至少一个为1.与半衰期延长部分或部分的连接增加毒素肽的体内半衰期，否则会很快退化。药物组合物包含该组合物和药学上可接受的载体。还公开了编码本发明组合物的DNA，包含DNA的表达载体和包含表达载体的宿主细胞。治疗自身免疫性疾病，例如但不限于多发性硬化，1型糖尿病，牛皮癣，炎性肠病，接触介导性皮炎，类风湿性关节炎，银屑病关节炎，哮喘，过敏，再狭窄，系统性硬化，纤维化，还公开了硬皮病，肾小球肾炎，干燥综合征，炎性骨吸收，移植排斥反应，移植物抗宿主病和狼疮以及预防或减轻多发性硬化症状的复发。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式